Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings.
Zürcher
G
G
Pharma Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Dingemanse
J
J
Da Prada
M
M
D000818:Animals; D001545:Benserazide / Q000493:pharmacokinetics / Q000494:pharmacology; D001577:Benzophenones / Q000493:pharmacokinetics / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D002230:Carbidopa / Q000493:pharmacokinetics / Q000494:pharmacology; D002394:Catechol O-Methyltransferase / Q000097:blood; D065098:Catechol O-Methyltransferase Inhibitors; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D006719:Homovanillic Acid / Q000097:blood; D006801:Humans; D007980:Levodopa / Q000493:pharmacokinetics / Q000494:pharmacology; D008297:Male; D009596:Nitrophenols; D010525:Peripheral Nerves / Q000187:drug effects* / Q000201:enzymology; D051381:Rats; D012435:S-Adenosylhomocysteine / Q000493:pharmacokinetics; D012436:S-Adenosylmethionine / Q000493:pharmacokinetics; D000077867:Tolcapone
D001577:Benzophenones; D065098:Catechol O-Methyltransferase Inhibitors; D009596:Nitrophenols; D007980:Levodopa; D001545:Benserazide; D012436:S-Adenosylmethionine; D012435:S-Adenosylhomocysteine; D000077867:Tolcapone; D002394:Catechol O-Methyltransferase; D002230:Carbidopa; D006719:Homovanillic Acid